 |
|
|
| |
Week 24 Primary Analysis of Cenicriviroc vs Efavirenz, in Combination with FTC/TDF, in Treatment-naïve HIV-1 Infected Adults with CCR5-tropic virus
|
| |
| |
Reported by Jules Levin
CROI 2013 Atlanta March 3-6
(Study 652-2-202; NCT01338883)
Joseph Gathe1, Jerry Cade2, Edwin DeJesus3, Judith Feinberg4, Jay Lalezari5, Javier O. Morales Ramirez6, Anthony Scarsella7, Michael Saag8, Melanie Thompson9, Eric Lefebvre10
1Therapeutic Concepts, Houston, TX, US; 2Nevada AIDS Res Ed Society, Las Vegas, NV, US; 3Orlando Immunology Ctr, Orlando, FL, US; 4Univ Cincinnati, Cincinnati, OH, US; 5Quest Clin Res, San Francisco, CA, US; 6Clin Res P.R., Inc.,
San Juan, Puerto Rico; 7Pacific Oaks Med Grp, Beverly Hills, CA, US; 8Univ Alabama at Birmingham, Birmingham, AL, US; 9AIDS Res Consortium of Atlanta, Atlanta, GA, US; 10Tobira Therapeutics Inc., San Francisco, CA, US
|
| |
|
|
|
|
|
